AU2020396807B2 - Treatment for acute myeloid leukemia or myelodysplastic syndrome - Google Patents

Treatment for acute myeloid leukemia or myelodysplastic syndrome

Info

Publication number
AU2020396807B2
AU2020396807B2 AU2020396807A AU2020396807A AU2020396807B2 AU 2020396807 B2 AU2020396807 B2 AU 2020396807B2 AU 2020396807 A AU2020396807 A AU 2020396807A AU 2020396807 A AU2020396807 A AU 2020396807A AU 2020396807 B2 AU2020396807 B2 AU 2020396807B2
Authority
AU
Australia
Prior art keywords
compound
dose
myeloid leukemia
patients
acute myeloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020396807A
Other languages
English (en)
Other versions
AU2020396807A1 (en
Inventor
Mark R. Bray
Graham Fletcher
Jacqueline M. Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of AU2020396807A1 publication Critical patent/AU2020396807A1/en
Application granted granted Critical
Publication of AU2020396807B2 publication Critical patent/AU2020396807B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020396807A 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome Active AU2020396807B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944876P 2019-12-06 2019-12-06
US62/944,876 2019-12-06
PCT/CA2020/051668 WO2021108918A1 (en) 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
AU2020396807A1 AU2020396807A1 (en) 2022-07-21
AU2020396807B2 true AU2020396807B2 (en) 2026-07-16

Family

ID=76221282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020396807A Active AU2020396807B2 (en) 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome

Country Status (12)

Country Link
US (1) US12533357B2 (enExample)
EP (1) EP4069246A4 (enExample)
JP (1) JP2023505301A (enExample)
KR (1) KR20220124177A (enExample)
CN (1) CN115397429A (enExample)
AU (1) AU2020396807B2 (enExample)
BR (1) BR112022011052A2 (enExample)
CA (1) CA3163796A1 (enExample)
IL (1) IL293623A (enExample)
MX (1) MX2022006910A (enExample)
TW (1) TWI880995B (enExample)
WO (1) WO2021108918A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
TWI926033B (zh) 2021-05-11 2026-05-21 美商歐瑞克製藥公司 類ｐｏｌｏ激酶４抑制劑
TW202333712A (zh) * 2021-12-22 2023-09-01 加拿大健康網路大學 於急性骨髓性白血病或淋巴瘤之治療
CN117180295A (zh) * 2023-09-13 2023-12-08 华东医院 一种用于治疗tp53突变髓系肿瘤的药物组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123946A1 (en) * 2010-04-06 2011-10-13 University Health Network Kinase inhibitors and method of treating cancer with same
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE
WO2019113311A1 (en) * 2017-12-06 2019-06-13 Ludwig Institute For Cancer Research Ltd Methods of treating cancer with plk4 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
EP3052102B1 (en) 2013-10-04 2019-12-04 Aptose Biosciences Inc. Compositions for treating cancers
TR201902875T4 (tr) * 2013-10-18 2019-03-21 Univ Health Network Plk-4 inhibitörünün tuz ve kristal formları.
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
KR20190129889A (ko) 2017-03-31 2019-11-20 노파르티스 아게 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법
EP3959209A4 (en) 2019-04-24 2022-12-28 University Health Network S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123946A1 (en) * 2010-04-06 2011-10-13 University Health Network Kinase inhibitors and method of treating cancer with same
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE
WO2019113311A1 (en) * 2017-12-06 2019-06-13 Ludwig Institute For Cancer Research Ltd Methods of treating cancer with plk4 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
UNIVERSITY HEALTH NETWORK, TORONTO: "Study of CFI-400945 Fumarate in Patients With...", NCT03187288, version 5, 13 Aug 2018. URL: https://clinicaltrials.gov/study/NCT03187288?a=5&tab=history#version-content-panel [retrieved 13 Aug 2025]. *
ZHAO Y., et al.; "Targeting Polo-like Kinase 4 for Therapeutic Benefit in the Patients with Diffuse Large B-Cell Lymphoma", Blood. 2019, vol 134(Supplement 1), 2568. *

Also Published As

Publication number Publication date
AU2020396807A1 (en) 2022-07-21
JP2023505301A (ja) 2023-02-08
US12533357B2 (en) 2026-01-27
EP4069246A1 (en) 2022-10-12
MX2022006910A (es) 2022-11-09
US20230010772A1 (en) 2023-01-12
CA3163796A1 (en) 2021-06-10
IL293623A (en) 2022-08-01
CN115397429A (zh) 2022-11-25
BR112022011052A2 (pt) 2022-08-16
EP4069246A4 (en) 2023-12-06
WO2021108918A1 (en) 2021-06-10
TW202134237A (zh) 2021-09-16
TWI880995B (zh) 2025-04-21
KR20220124177A (ko) 2022-09-13